PMID- 25860241
OWN - NLM
STAT- MEDLINE
DCOM- 20160909
LR  - 20220331
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 11
DP  - 2015
TI  - Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with 
      ABVD-based therapy.
PG  - 3096-102
LID - 10.3109/10428194.2015.1038709 [doi]
AB  - Ferritin levels might correlate with disease activity in classical Hodgkin 
      lymphoma (cHL). We analyzed the prognostic significance of the ferritin value at 
      diagnosis in 173 cHL patients treated with ABVD between 2003 and 2013. The 5-year 
      overall survival (OS) and progression-free survival (PFS) probabilities were 80% 
      and 64%, respectively. Patients with ferritin >/= 350 mug/l [high ferritin group 
      (HF), n = 62] were more likely to have advanced stage disease, B-symptoms and 
      higher International Prognostic Score (IPS) compared with patients with ferritin 
      < 350 mug/l [low ferritin group (LF), n = 111]. The complete remission (CR) rate 
      and 5-year PFS and OS probabilities were lower in HF vs. LF patients (69% vs. 
      89%, p = 0.025; 40% vs. 78%, p < 0.001; 61% vs. 90%, p = 0.001; respectively). 
      Multivariate analysis revealed that advanced stage (p = 0.001) and ferritin 
      levels >/= 350 mug/l (p = 0.002) were independent predictors for PFS. In conclusion, 
      the ferritin level at diagnosis is a useful prognostic marker for cHL.
FAU - Fernandez-Alvarez, Ruben
AU  - Fernandez-Alvarez R
AD  - a Hematology Department of Hospital de Cabuenes , Gijon , Spain.
FAU - Gonzalez-Rodriguez, Ana P
AU  - Gonzalez-Rodriguez AP
AD  - b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
FAU - Gonzalez, M Esther
AU  - Gonzalez ME
AD  - a Hematology Department of Hospital de Cabuenes , Gijon , Spain.
FAU - Rubio-Castro, Arturo
AU  - Rubio-Castro A
AD  - a Hematology Department of Hospital de Cabuenes , Gijon , Spain.
FAU - Dominguez-Iglesias, Francisco
AU  - Dominguez-Iglesias F
AD  - a Hematology Department of Hospital de Cabuenes , Gijon , Spain.
FAU - Solano, Jackeline
AU  - Solano J
AD  - b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
FAU - Alonso-Nogues, Eva
AU  - Alonso-Nogues E
AD  - b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
FAU - Fernandez-Alvarez, Carmen
AU  - Fernandez-Alvarez C
AD  - a Hematology Department of Hospital de Cabuenes , Gijon , Spain.
FAU - Zanabili, Yahya
AU  - Zanabili Y
AD  - c Hematology Department of Hospital San Agustin , Aviles , Spain.
FAU - Alonso, Jose Manuel
AU  - Alonso JM
AD  - d Hematology Department of Hospital Valle del Nalon , Langreo , Spain.
FAU - Payer, Angel Ramirez
AU  - Payer AR
AD  - b Hematology Department of Hospital Central de Asturias , Oviedo , Spain.
FAU - Vicente, Jose Maria
AU  - Vicente JM
AD  - e Hematology Department of Hospital Alvarez Buylla , Mieres , Spain.
FAU - Medina, Jesus
AU  - Medina J
AD  - c Hematology Department of Hospital San Agustin , Aviles , Spain.
FAU - Sancho, Juan M
AU  - Sancho JM
AD  - f Hematology Department of ICO-Hospital Germans Trias i Pujol , Jose Carreras 
      Research Institute , Badalona , Universitat Autonoma de Barcelona , Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150512
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 9007-73-2 (Ferritins)
RN  - ABVD protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers
MH  - Bleomycin/therapeutic use
MH  - Combined Modality Therapy
MH  - Dacarbazine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Ferritins/*blood
MH  - Hodgkin Disease/*blood/diagnosis/drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - ROC Curve
MH  - Radiotherapy
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Biomarker
OT  - Hodgkin lymphoma
OT  - ferritin
OT  - lymphoma
OT  - prognosis
EDAT- 2015/04/11 06:00
MHDA- 2016/09/10 06:00
CRDT- 2015/04/11 06:00
PHST- 2015/04/11 06:00 [entrez]
PHST- 2015/04/11 06:00 [pubmed]
PHST- 2016/09/10 06:00 [medline]
AID - 10.3109/10428194.2015.1038709 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015;56(11):3096-102. doi: 10.3109/10428194.2015.1038709. Epub 
      2015 May 12.